EP0628043A1 - 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist - Google Patents

2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Info

Publication number
EP0628043A1
EP0628043A1 EP93904797A EP93904797A EP0628043A1 EP 0628043 A1 EP0628043 A1 EP 0628043A1 EP 93904797 A EP93904797 A EP 93904797A EP 93904797 A EP93904797 A EP 93904797A EP 0628043 A1 EP0628043 A1 EP 0628043A1
Authority
EP
European Patent Office
Prior art keywords
treatment
treating
mania
vomiting
migraine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93904797A
Other languages
German (de)
English (en)
French (fr)
Inventor
Maurice W. Gittos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Priority to EP93904797A priority Critical patent/EP0628043A1/en
Publication of EP0628043A1 publication Critical patent/EP0628043A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Definitions

  • This invention relates to 5-chloro-2,3-dihydro-2,2- dimethylbenzofuran-7-carboxylie acid-octahydro-3-hydroxy- 5 2,6-methano-2H-quinolizin-8-yl ester, a novel 5-HT 3 -receptor antagonist, its method of preparation, and to its end-use application in the treatment of conditions responsive to 5-HT 3 receptor antagonism such as radio- and chemo-therapeu ⁇ tically-induced nausea and vomiting, • __ ⁇ « • the treatment of
  • the wavy line bonding the oxygen atom of the ester moiety to the 8-position of the octahydro-2,6-methano- 2H-quinolizin moiety indicates that the bonding may be in the endo (trans) or the exo (cis) configuration.
  • the preferred configuration is endo.
  • the pharmaceutically acceptable acid addition salts referred to above can be non-toxic salts with suitable acids such as those with inorganic acids, for example, hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids; or with organic acids such as organic carboxylic acids r for example, acetic, propionic, glycolic, maleic, hydroxymaleic, malic, tartaric, citric, salicylic, 2-acetyl- oxybenzoic, nicotinic or isonicotinic; or organic sulfonic acids, for example, methanesulfonic, ethanesulfonic, 2- hydroxyethanesulfonic, 4-toluenesulfonic or 2-naphthalene- sulfonic.
  • suitable acids such as those with inorganic acids, for example, hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids
  • organic acids such as organic carboxylic acids r for example, acetic, propi
  • Step A' (Alternate to Step A): Using trichlorometh l chloroformate 5-Chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester
  • the racemic mixture can be separated into its separate enantiomers by standard techniques.
  • the compounds of the present invention block the M receptors for 5-hydroxytryptamine (5HT) on afferent sensory neurons otherwise known as 5HT 3 -receptors.
  • the activity of the compounds of this invention against the 5HT 3 -receptor can be assessed by determining their pA 2 values in the isolated rabbit heart as described by J. R. Fozard et al., Eur. J. Pharmacol. 5£, 195-210 (1979).
  • the in ⁇ i ⁇ o 5HT 3 -receptor antagonist activity can be assessed by measurement of the effect of the compound on the Von Bezold- Jarisch reflex induced by 5HT injected intravenously into the rat (see Paintal A. S., Physiol. Rev. 5_3, 159-227 (1973); J. R. Fozard, Naunyn-Schmiedeberg's Arch. Pharmacol. 326, 36-44 (1984).
  • the compounds of this invention may be utilized in a variety of treatments.
  • the compounds of the present invention are useful in treating conditions responsive to 5-HT 3 receptor antagonism.
  • conditions responsive to 5-HT 3 receptor antagonism are well known to those skilled in the art.
  • Some examples of these conditions are treating anxiety, psychosis, glaucoma and for stimulating gastric motility (U.S. Patent No. 5,011,846), treatment of panic disorders and/or agoraphobia or obsessive compulsive disorders (Patent No. EP 422,154); treatment of autism or other disorder originating in childhood in which there is mental retardation (Patent No. EP 450,757); treatment of cognitive disorders such as Alzheimer's Disease (U.S. Patent Application Serial No. 806,987); production of orexiogenic effect (U.S. Patent Application Serial No.
  • Patent No. GB 2,193,633 Patent No. GB 2,193,633
  • Patent No. EP 279,114 and GB 2,206,788 treatment of lung embolism
  • Patent No. GB 2,231,265 treatment of cough and/or bronchoconstriction
  • Doses administered to patients are within the range of about 0.01 to about 10 mg per kilogram of body- weight, with 35 0.01 to 1 mg per kilogram of body weight being preferred for parenteral administration and 0.25 to 1 mg per kilogram of body weight upon enteral administration.
  • dosage required for the treatment of the foregoing disease states will depend upon such factors as the severity and stage of the particular disease, the age and condition of the patients as such other normal factors taken into consideration by the attending diagnostician.
  • patient means warm-blooded animals such as rats, mice, dogs, cats, guinea pigs, primates and humans.
  • treat means to prevent or alleviate the patient's disease or condition.
  • the compounds of Formula (I) can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders, such as acacia, cornstarch, or gelatin, disintegrating agents such as potato starch or algenic acid, and a lubricant such as stearic acid or magnesium stearate.
  • binders such as acacia, cornstarch, or gelatin
  • disintegrating agents such as potato starch or algenic acid
  • a lubricant such as stearic acid or magnesium stearate.
  • Liquid preparations are prepared by dissolving the active ingredient in an aqueous or non- aqueous pharmaceutically acceptable solvent which may also contain suspending agents, sweetening agents, flavoring agents, and preservative agents as are known in the art.
  • the compounds may be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension.
  • suitable pharmaceutical carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin.
  • the pharmaceutical carrier may also contain preservatives, buffers, etc. as are known in the art.
  • transdermal devices are described in U.S. Pat. Nos. 3,742,951, 3,797,494, 3,996,934, and 4,031,894 incorporated herein. These devices generally contain a backing member which defines one of its face surfaces, an active agent permeable adhesive layer defining the other face surface and at least one reservoir containing the active agent interposed between the face surfaces.
  • the active agent may be contained in a plurality of microcapsules distributed throughout the permeable adhesive layer. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or ucosa of the recipient.
  • the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient.
  • the encapsulating agent may also function as the membrane.
  • the pharmaceutically active compound is contained in a matrix from which it is delivered in the desired gradual, constant and controlled rate.
  • the matrix is permeable to the release of the compound through diffusion or microporous flow. The release is rate controlling.
  • Such a system, which requires no membrane is described in U.S. Pat. No. 3,921,636 incorporated herein. At least two types of release are possible in these systems. Release by diffusion occurs when the matrix is non-porous.
  • the pharmaceutically effective compound dissolves in and diffuses through the matrix itself. Release by microporous flow occurs when the pharmaceutically effective compound is transported through a liquid phase in the pores of the matrix.
  • compositions of the present invention are prepared in a manner well known perse in the pharmaceutical art and usually comprise one or more active compounds of the invention in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefor.
  • the active ingredient will usually be mixed with a carrier, or diluted by a diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other container.
  • a carrier or diluent may be solid, semisolid or liquid material which serves as a vehicle, excipient or medium for the active ingredient. Suitable carriers or diluents are well known per se. See Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, incorporated herein, for a description of the preparation of such formulations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP93904797A 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist Withdrawn EP0628043A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP93904797A EP0628043A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24
EP92400474 1992-02-24
EP93904797A EP0628043A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist
PCT/US1993/000880 WO1993017019A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Publications (1)

Publication Number Publication Date
EP0628043A1 true EP0628043A1 (en) 1994-12-14

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93904797A Withdrawn EP0628043A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Country Status (14)

Country Link
EP (1) EP0628043A1 (enrdf_load_html_response)
JP (1) JPH07504192A (enrdf_load_html_response)
KR (1) KR100287933B1 (enrdf_load_html_response)
AU (1) AU675060B2 (enrdf_load_html_response)
CA (1) CA2130563C (enrdf_load_html_response)
FI (1) FI105917B (enrdf_load_html_response)
HU (1) HU216831B (enrdf_load_html_response)
IL (1) IL104821A (enrdf_load_html_response)
MX (1) MX9300948A (enrdf_load_html_response)
NO (1) NO943101L (enrdf_load_html_response)
NZ (1) NZ249346A (enrdf_load_html_response)
TW (1) TW226374B (enrdf_load_html_response)
WO (1) WO1993017019A1 (enrdf_load_html_response)
ZA (1) ZA931146B (enrdf_load_html_response)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2672500A (en) 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
JP5241484B2 (ja) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080727T3 (es) * 1988-02-23 1996-02-16 Merrell Pharma Inc Uso de quinolizina y derivados de quinolizinona en la fabricacion de medicamentos.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9317019A1 *

Also Published As

Publication number Publication date
TW226374B (enrdf_load_html_response) 1994-07-11
NO943101D0 (no) 1994-08-23
KR950700297A (ko) 1995-01-16
MX9300948A (es) 1993-08-01
FI943872L (fi) 1994-08-23
ZA931146B (en) 1993-09-14
HUT68249A (en) 1995-06-28
CA2130563A1 (en) 1993-09-02
JPH07504192A (ja) 1995-05-11
CA2130563C (en) 1997-11-11
AU3603493A (en) 1993-09-13
NO943101L (no) 1994-08-23
AU675060B2 (en) 1997-01-23
FI943872A0 (fi) 1994-08-23
NZ249346A (en) 1995-10-26
HU9402436D0 (en) 1994-10-28
IL104821A (en) 1997-01-10
FI105917B (fi) 2000-10-31
IL104821A0 (en) 1993-06-10
HU216831B (hu) 1999-09-28
WO1993017019A1 (en) 1993-09-02
KR100287933B1 (ko) 2001-05-02

Similar Documents

Publication Publication Date Title
US5011846A (en) Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
JPH0662607B2 (ja) 新規三環式化合物
JP2542225B2 (ja) ヘキサヒドロ−８−ヒドロキシ−２，６−メタノ−２ｈ−キノリジン−３（４ｈ）−オンのエステル類及び関連化合物類
EP0546181B1 (en) Indole derivatives and their use as serotonin antagonists
EP0518767B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
IE83573B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
US5955470A (en) Derivatives of amide analogs of certain methano bridged quinolizines
EP0628043A1 (en) 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist
US5508287A (en) 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
EP0329932B1 (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
CZ286649B6 (cs) 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano-/2,3-e/indol-8-onové deriváty a farmaceutický prostředek s jejich obsahem
US5258384A (en) S-11-hydroxy-10-methylaporphine and its biologically active salt forms as 5HT1A inhibitors
EP0329903A1 (en) Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma
US5910501A (en) Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolozin-3(4H)-one and related compounds for treating cognitive disorders
CA2195157A1 (en) (1h-indol-4-yl)-piperidine or tetrahydropyridine ethylamines and ethylcarboxamides
EP0329904A1 (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
EP0804433A1 (en) Indole derivative for the treatment of migraine
JPH05230057A (ja) 光学活性インダゾール―３―カルボキサミド誘導体及びそれを有効成分とする制吐剤
EP0329905A1 (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility
US5945118A (en) Indole derivative for the treatment of migraine
JPH01165588A (ja) ５，６，７，８‐テトラハイドロ‐４ｈ‐イソオキサゾロ〔４，５‐ｃ〕アゼピン誘導体、異性体およびそれらの酸付加塩

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940818

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERRELL PHARMACEUTICALS INC.

17Q First examination report despatched

Effective date: 19980406

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000509